Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy.
A case is reported in which a child with Duchenne muscular dystrophy received a dose of sugammadex to reverse a rocuronium-induced profound neuromuscular block. Sugammadex is the first selective relaxant binding agent and reverses rocuronium- and vecuronium-induced neuromuscular block. A fast and efficient recovery from profound neuromuscular block was achieved, and no adverse events or other safety concerns were observed.
de Boer
Hans D
HD
Department of Anesthesiology and Pain Medicine, Martini General Hospital Groningen, Groningen, The Netherlands. HD.de.Boer@mzh.nl
van Esmond
Jan
J
Booij
Leo H J D
LH
Driessen
Jacques J
JJ
D000732:Androstanols / Q000037:antagonists & inhibitors*; D000768:Anesthesia, General / Q000379:methods; D002648:Child; D006801:Humans; D006810:Humeral Fractures / Q000601:surgery; D008297:Male; D020388:Muscular Dystrophy, Duchenne / Q000150:complications*; D019148:Neuromuscular Blockade; D003473:Neuromuscular Nondepolarizing Agents / Q000037:antagonists & inhibitors*; D000077123:Rocuronium; D000077122:Sugammadex; D016896:Treatment Outcome; D047408:gamma-Cyclodextrins / Q000494:pharmacology*
D000732:Androstanols; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D000077123:Rocuronium